Biotech | May 21, 2022
AbbVie submits NDA for treatment of advanced Parkinson’s disease
If approved, ABBV-951 will offer patients the first continuous subcutaneous delivery of carbidopa/levodopa prodrugs
If approved, ABBV-951 will offer patients the first continuous subcutaneous delivery of carbidopa/levodopa prodrugs
The patient, who was previously diagnosed with osteoarthritis, was prescribed hip replacement surgery as the best and most effective solution for his condition
Risk management plans can serve as a safeguard, helping manufacturers prepare for and respond to hazards that could lead to drug supply disruptions and shortages
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection
Leading pharma companies are achieving rapid, large-scale performance improvements using a multifaceted approach that realizes short-term gains & builds long-term capabilities at the same time
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
This cost-effective tool will be of immense benefit to other high burden countries as well.
This new fund is amongst the largest for the sector in India
Multiples is the first private equity (PE) investor in the company
It is developing the drug candidate to potentially treat immunological diseases
Subscribe To Our Newsletter & Stay Updated
